Skip to content

A Trial of Toric Versus Non-toric Intraocular Lenses in Phacoemulsification Cataract Surgery

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01712503
Enrollment
190
Registered
2012-10-23
Start date
2013-01-31
Completion date
2014-01-31
Last updated
2012-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Astigmatism, Cataract

Keywords

Cataract, Astigmatism, Toric, Phacoemulsification, Intraocular lens

Brief summary

This is a randomised controlled trial that formally compares intra-ocular lenses, which can be used in cataract surgery, one of which is the standard 'monofocal' lens, and the other is the newer toric lens which can correct astgimatism. The null hypothesis is that both intra-ocular lenses give the same visual outcome in cataract surgery. The alternative hypothesis is that the toric lens, provides a better unaided (without glasses) vision, by correcting the participant's astigmatism. It has been decided to conduct a randomised controlled trial of the two lenses, as although the toric lenses are endorsed by many case series (which show a reduction in astigmatism), they have not been formally compared to the standard lens. An RCT will enable the formal comparison. It is expected that this trial will take approximately a year to conduct: six months of recruitment and six months of follow-up. A further six months will be required to analyse the data and prepare a manuscript for publication. The investigators do not plan to conduct an interim analysis or report as this is a short-trial (six months follow-up) using two alternative lens that are CE marked and already widely used. Participants who have both cataract and astigmatism will be identified from the GP/optometrist referral letter. They will be seen in specially designated clinics for this research study, which will run alongside the routine cataract 'one' stop clinics at St Richard's Hospital and Worthing Hospital. This will allow for those patients who wish to be part of the study to have all the necessary examination done in one visit and for those who decline participation to be seen in the regular cataract clinic. Potential participants will be sent the research trial information (appendix A) with their appointment letter. After introducing himself the researcher (who is also a senior cataract surgeon at Western Sussex Hospital Trust), will check if potential participants have had the opportunity to read the trial information that they were sent, or give participants a further copy as required. The key points of the trial will be re-iterated by the researcher and they will be invited to ask any questions about the trialThe researcher will check that the potential participant has read and understood the participant information leaflet. They will answer any questions that the potential participant has and will then take signed consent from those willing to participate. Only one eye (the 'trial eye') from each patient will be used in the trial. In patients with bilateral cataract, one eye will be selected as the trial eye. This will be the eye that the participant prefers, after consultation with the researcher or surgeon, to have operated first. The participant will be allocated a unique study reference number. Patients who decline to take part in the trial will be offered cataract surgery as per usual WSHT/NHS procedure.

Interventions

DEVICEPhacoemulsfication cataract surgery and intra-ocular lens implant

Sponsors

Rayner Intraocular Lenses Ltd
CollaboratorUNKNOWN
Western Sussex Hospitals NHS Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Symptomatic cataract for which the patient desires surgery 2. Corneal astigmatism of greater than or equal to 2 dioptres 3. No significant ophthalmic comorbidity

Exclusion criteria

1. \<18 years of age 2. Significant ophthalmic co-morbidity 3. Pregnant 4. Medically unfit for cataract surgery 5. Not competent to give consent

Design outcomes

Primary

MeasureTime frame
Unaided LogMAR visual acuity at 2 months post-operatively

Secondary

MeasureTime frame
Unaided LogMAR visual acuity at 2 weeks and 6 months post-operatively
Corrected visual acuity at 2 months and 6 months post-operatively
Residual spherical and cylindrical prescriptions at 2 weeks, 2 months and 6 months post-operatively
Patients quality of life questionnaire to assess subjective vision, glare at day/night, subjective colour perception, other symptoms.

Countries

United Kingdom

Contacts

Backup ContactSaul Rajak
saul.rajak@lshtm.ac.uk
Primary ContactMasoud Teimory
masoud.teimory@wsht.nhs.uk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026